Another piece of bipartisan legislation was introduced last week that seeks to promote biosimilars.
Another piece of bipartisan legislation was introduced last week that seeks to promote biosimilars.
Senator Mike Enzi, R-Wyoming, and Senator Maggie Hassan, D-New Hampshire, unveiled legislation to enhance education about biosimilars in an effort to increase competition and lower the cost of biologics.
According to a joint statement, the bill has 3 main parts: requiring HHS to create a central website for educational resources on biosimilars; requiring the HHS secretary to establish a database to help medical professionals easily compare data associated with biologic and biosimilar products; and establishing incentives for medical providers to learn more about biosimilars.
It aims to boost the confidence level of both physicians and patients regarding biosimilars’ safety and effectiveness.
The 2 senators cite the slow uptake of biosimilars in the US market, saying that while just 2% of Americans use biologics, they make up 40% of total spending on prescription drugs.
“We are not benefiting from cheaper prescription drug alternatives like biosimilars as much as we should,” Enzi said. “Biosimilars are one of the ways we can do something about healthcare costs without just shifting them elsewhere in the system or implementing administrative price controls. This legislation would help increase confidence in lower-cost biosimilar products, which could drive down drug costs for Americans.”
“Biosimilars have the potential to reduce how much Granite Staters and Americans are spending on drugs, but there is a lack of awareness about these products,” Hassan added. “This bipartisan legislation would help improve awareness and understanding of biosimilars, which in turn could help increase the use of these products and save money for consumers and the federal government.”
A 2017 study by the RAND Corporation estimated the cost savings potential of biosimilars to be $54 billion over 10 years.
Also last week, the Senate Committee on Health, Education, Labor, and Pensions (HELP) released a bill that includes several components related to biosimilars, including one that would require updates to the FDA’s Purple Book, which provides stakeholders with information on biologics. Another part addresses the abuse of citizen petitions.
In addition, that bipartisan bill, sponsored by chairman Lamar Alexander, R-Tennessee, and ranking member Patty Murray, D-Washington, stipulates that the FDA would be required to establish a website for stakeholder education on biologics, including biosimilars and interchangeable products, and allows for the development and improvement of continuing medical education for providers on these topics.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.